The pharmacology of T-type calcium channels is in complex because many drugs have been found to block T-type currents. [1] [2] [3] Unfortunately, none of these compounds has high selectivity for these channels. Mibefradil has been marketed worldwide for the treatment of hypertension and angina for a short period before it was withdrawn due to its pharmacokinetic and pharmacodynamic interactions with some other drugs such as terfenadine, astemizole, cisapride, cyclosporine, tricyclic antidepressants. 4 Mibefradil binds to skeletal muscle L-type calcium channels and brain voltage-gated sodium channels with dissociation constants of 2.3 and 17 nM, respectively. 5 It also can block potassium and chloride channels. 6 Obviously, this makes it not an ideal tool for in vitro or in vivo studies on T-type channels. Therefore, more potent and selective blockers are required to study the fundamental function of T-type channel and the related pathophysiological diseases such as epilepsy, neuronal pain, hypertension, congestive heart failure, and cancer. [7] [8] Recently, our group have reported the identification of 3,4-dihydroquinazoline derivatives as a novel scaffold, which are potent and selective T-type calcium blockers. [9] [10] These compounds also exhibited the anti-cancer activity in vitro via cellcycle arrest mechanism. [11] [12] As a continuous work, three compounds (1-3) with the highest T-channel channel selectivity (No blocking against N-type channel) were selected among the chemical library of 3,4-dihydroquinazoline and evaluated for the blocking effect on the hERG potassium channel, [13] [14] which is known for its contribution to the electrical activity of the heart that coordinates the heart's beating: both of % inhibitions at 10 µM concentration and the molar concentrations of compounds needed to produce 50% inhibition of peak currents (IC50) were measured by the whole-cell patch-clamp method. 15 The data were summarized in Table 1 with mibefradil as a positive control for comparison. Based on the IC50 data in Table 1 , 1-3 compounds exhibited low selectivity over hERG channel (T-type/hERG ratio = 3.43, 4.39 and 7.56, respectively) but higher than mibefradil (1.04). This result means that these compounds can distinguish N-type from T-type calcium channel perfectly but not hERG potassium channel effectively. Furthermore, the pharmacokinetic parameters of all compounds were evaluated after single oral dose (20 mg/kg) in the rat and summarized in Table 2 . These data demonstrate that compounds 1 and 3 exhibit higher volume of distribution but faster plasma clearance than compound 2. It is inferred that compound 2 has both proper absorption in gastrointestinal system (Cmax and AUC) and metabolic stability (t1/2 = 1.6 h) based on these parameters. In addition, we found the 22% oral bioavailability of compound 2 particularly gratifying when compared with the poor oral bioavailability of another two compounds.
Of the three T-type calcium channels, the Cav3.1 (α1G) and Cav3.3 (α1I) subtypes are primarily expressed in the brain, while Cav3.2 (α1H) has a broader central and peripheral expression. [16] [17] [18] In addition, T-type channels are highly expressed in the thalamus and cortex and play important roles in thalamocortical signaling. 19 Recent reports from some laboratories have disclosed that selective T-type calcium channel blockers show in vivo efficacy in epilepsy and tremor models. [20] [21] Based on these reports, therefore, our 3,4-dihydroquinazoline compound, in particular compound 2 which has both proper selective/potent T-type channel blocking effect and pharmacokinetic profile, was evaluated for the anti-tremor activity using two mouse model: harmaline-induced tremor mouse model 22 and GABAA receptor α1 subunit-null mouse model. 23 It has been well known that harmaline, a fluorescent psychoactive indole alkaloid from the group of harmala alkaloids, induces tremor in animals. 24 Thus, harmaline in saline (20 mg/kg) was injected subcutaneously in order to induce tremor in male ICR mouse. After 15 min when tremor had fully developed, compound 2 in 10% DMSO/saline solution was injected intraperitoneally. Then, the tremor-related motion data was obtained for five successive 20-min epochs and summarized in Table 3 . As a result, compound 2 suppressed harmaline-induced tremor by 44.7% and 53.3% at 20 -40 and 40 -60 min after injection respectively.
In the case of GABAA receptor α1 subunit-null mouse model which exhibits postural and kinetic tremor and motor incoordination that is characteristic of essential tremor disease, the tremor-related motion data was obtained four times at a specified time after compound treatment and summarized in Table 3 . As a result, compound 2 suppressed tremor by 58.0% at 10 mg/kg dose and by 82.2% at 20 mg/kg dose, respectively, 30 min post injection. This result suggests that 3,4-dihydroquinazoline compound would be developed as potential therapeutics for the tremor.
In summary, 3,4-dihydroquinazoline derivative (2) with proper T-type channel selectivity/activity and oral pharmacokinetic profile was evaluated for anti-tremor activity. This compound suppressed tremor in two tremor animal models effectively. This suggests that 3,4-dihydroquinazoline compound has considerable potential as an anti-tremor agent together with the previously reported anti-cancer agent. [11] [12] 
